X4 Pharmaceuticals financials
$2.90−3.81%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.8M | $2.7M | $2.6M | $1.8M | $2.0M | $28.8M | $1.4M | $560.0K | $563.0K | $0.00 | $0.00 | $0.00 |
| Gross profit | $7.2M | $2.1M | $2.2M | $1.4M | $1.6M | $24.1M | $1.1M | $333.0K | $295.0K | $0.00 | $0.00 | $0.00 |
| Gross margin | 81.6% | 77.9% | 85.8% | 80.1% | 83.5% | 83.6% | 78.9% | 59.5% | 52.4% | — | — | — |
| Operating income | -$16.4M | -$20.3M | -$23.7M | -$27.5M | -$26.2M | -$9.4M | -$35.7M | -$34.5M | $71.1M | -$37.3M | -$25.2M | -$27.2M |
| Net income | -$16.2M | -$20.2M | -$23.9M | -$29.8M | -$25.7M | $282.0K | -$39.8M | -$36.7M | $90.8M | -$51.8M | -$19.1M | -$2.3M |
| Net margin | −183.5% | −747.5% | −931.7% | −1689.2% | −1304.7% | 1.0% | −2776.9% | −6552.9% | 16133.7% | — | — | — |
| Diluted EPS | $-0.13 | $-0.16 | $-0.21 | $-0.69 | $-3.47 | $0.04 | $-5.90 | $-5.48 | $13.57 | $-7.77 | $-2.88 | $-0.30 |
| EBITDA | -$15.4M | -$20.1M | -$23.5M | -$27.3M | -$25.9M | -$9.0M | -$35.4M | -$34.2M | $71.3M | -$37.2M | -$25.1M | -$27.1M |
| Operating cash flow | -$20.8M | -$19.6M | -$15.5M | -$27.8M | -$29.9M | -$12.4M | -$33.0M | -$34.0M | -$30.3M | -$33.6M | -$27.7M | -$20.8M |
| Free cash flow | -$20.8M | -$19.6M | -$15.5M | -$27.8M | -$29.9M | -$12.4M | -$33.0M | -$34.1M | -$30.4M | -$33.7M | -$27.8M | -$20.8M |
| Diluted shares | 126.3M | 126.3M | 111.6M | 43.3M | 7.4M | 6.9M | 6.8M | 6.7M | 6.7M | 6.7M | 6.7M | 6.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $195.1M | $216.9M | $217.0M | $69.6M | $39.2M | $40.3M |
| Short-term investments | $12.9M | $16.8M | $35.9M | $52.6M | $23.7M | $46.7M |
| Total debt | $76.8M | $76.5M | $76.3M | $76.1M | $75.8M | $75.6M |
| Total assets | $253.1M | $270.3M | $290.5M | $163.6M | $105.2M | $130.0M |
| Total liabilities | $97.6M | $101.8M | $104.2M | $101.9M | $101.2M | $107.1M |
| Shareholders' equity | $155.5M | $168.4M | $186.3M | $61.6M | $4.0M | $22.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology